Pharma & R&D
Lilly’s Mounjaro Outperforms Other GLP-1 Drugs in Some Diabetes Patients
By Intent.Health Team • May 29, 2026
What’s happening
Mounjaro from Eli Lilly and Company showed stronger results than competing GLP-1 medicines in some patients with type 2 diabetes.
The study suggested better blood-sugar control and treatment outcomes for certain groups of patients.
What’s changing / Business impact
The findings strengthen Lilly's position in the highly competitive diabetes and obesity drug market.
Why this matters
GLP-1 medicines have become one of the biggest pharmaceutical markets in the world because they are used for both diabetes and weight management.